Thera-SAbDab

DOSTARLIMAB

>   Structural Summary
TherapeuticDostarlimab
TargetPDCD1
Heavy ChainEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSS
Light ChainDIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year Recommended2019
Companies InvolvedAnaptysBio, European Network of Gynaecological Oncological Trial Groups, GlaxoSmithKline, TESARO
Conditions Approvedna
Conditions ActiveFallopian tube cancer, Ovarian cancer, Peritoneal cancer, Endometrial cancer, Non-small cell lung cancer, Solid tumours
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]